Transcriptomic validation and clinical translation of CCDC78 as a prognostic biomarker in colorectal cancer
Authors:
- 1 January 2025
- journal article
- Published by e-Century Publishing Corporation in American Journal of Cancer Research
- Vol. 15 (7) , 3245-3266
Abstract
This study investigates CCDC78 as a potential prognostic biomarker in colorectal cancer (CRC), incorporating both clinical correlation and functional validation. Analysis of 135 paired tumor and adjacent tissues revealed significantly elevated CCDC78 expression in tumor tissues (P<0.001), and higher expression levels were associated with markedly lower 5-year survival rates (P=0.001). Time-dependent ROC curves demonstrated robust prognostic performance at 12, 36, and 60 months (AUCs of 0.85, 0.84, and 0.82, respectively). In vitro assays showed that CCDC78 overexpression significantly enhanced cell proliferation, migration, and invasion (P<0.05), whereas siRNA-mediated knockdown suppressed these phenotypes and increased apoptosis (P<0.01). Cox regression analyses identified CCDC78 as an independent prognostic factor (P=0.02). Notably, despite similar baseline expression across CRC cell lines, SW480 cells were more sensitive to knockdown, while HCT116 cells more strongly recapitulated the overexpression phenotype. TCGA pan-cancer analysis showed upregulated CCDC78 in various tumors, including CRC, adrenocortical carcinoma (ACC), bladder cancer (BLCA), and kidney renal clear cell carcinoma (KIRC), reinforcing its broad oncogenic relevance. Correlation analyses linked high CCDC78 expression to older age, poor tumor differentiation, advanced TNM stage, lymph node metastasis, and distant metastasis. Immune profiling revealed negative associations with 11 immune cell types but a positive correlation with NK CD56 bright cells. Gene set enrichment analysis (GSEA) implicated CCDC78 in interferon-JAK-STAT, RIG-I/NFκB, and WNT signaling pathways. Altogether, these findings suggest that CCDC78 promotes CRC progression through enhancing tumor cell aggressiveness and modulating the immune microenvironment, underscoring its potential as a prognostic biomarker and therapeutic target.Keywords
This publication has 27 references indexed in Scilit:
- Synergistic diagnostic value of circulating tumor cells and tumor markers CEA/CA19-9 in colorectal cancerScandinavian Journal of Gastroenterology, 2022
- Functional genetic screen identifies ITPR3/calcium/RELB axis as a driver of colorectal cancer metastatic liver colonizationDevelopmental Cell, 2022
- [Establishment of a prediction model for colorectal cancer immune cell infiltration based on the cancer genome atlas (TCGA) database].2022
- A novel prognostic immunoscore based on The Cancer Genome Atlas to predict overall survival in colorectal cancer patientsBioscience Reports, 2021
- Beta-1 syntrophin (SNTB1) regulates colorectal cancer progression and stemness via regulation of the Wnt/β-catenin signaling pathwayAnnals of Translational Medicine, 2021
- CXCL1 Regulated by miR-302e Is Involved in Cell Viability and Motility of Colorectal Cancer via Inhibiting JAK-STAT Signaling PathwayFrontiers in Oncology, 2021
- The inflammatory pathogenesis of colorectal cancerNature Reviews Immunology, 2021
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesCA: A Cancer Journal for Clinicians, 2021
- Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancerMolecular Cancer, 2019
- Dominant Mutation of CCDC78 in a Unique Congenital Myopathy with Prominent Internal Nuclei and Atypical CoresThe American Journal of Human Genetics, 2012